Xenetic Bio (XBIO) - Gross Profit Ratio

Corporate emblem and logo of Xenetic Biosciences (XBIO)

Xenetic Biosciences (XBIO) gross margin as a percentage of revenue reflects the impact of licensing DNase technologies to oncology centers, with the 0.00 level serving as a critical benchmark. Stability in these metrics is supported by streamlined collaboration with contract laboratories during drug development. High efficiency is achieved through a strategic focus on R&D and the collection of royalties from pharma behemoths, which completely eliminates manufacturing costs.

XBIO Xenetic Bio Gross Margin (07/04/2022 - 11/20/2026)

Financial and market metric breakdowns for Xenetic Biosciences Inc. (XBIO)

- stock value and consensus price forecast:
- cash position and cash flow details:
Fundamental valuation:XBIO - xeneticbio.com
Manufactured products of Xenetic Biosciences, Inc.

For Xenetic Biosciences (XBIO), which is developing an oncology ecosystem based on DNase, gross margin serves as an indicator of innovation monetization efficiency. This metric is calculated as the share of revenue minus direct production costs, allowing for an assessment of the fundamental profitability of each therapy unit. By analyzing gross profitability trends, an investor can determine how successfully the company's technological advantage is converted into operating profit.

Main competitors

Gross Profit Margin BeiGene Ltd. (ONC)|Return on Gross Profit HALO|Gross Profitability RVMD|Return on Gross Profit AAPG (Ascentage)|Return on Gross Profit cgoncology.com CGON|UroGen Pharma - Return on Gross Profit|Gross Profit Rate BCAX|PSNL - Gross Profitability|Return on Sales by Gross Profit Erasca Oncology ERAS|delcath.com (DCTH) - Gross Profitability|Y-mAbs Therapeutics - Gross Profit Rate|AURA (Aura Biosciences Inc) - Gross Margin|Gross Profit Margin candeltx.com CADL|Gross Margin ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Gross Profit Rate|Gross Profitability Actuate Therapeutics, Inc. ACTU|citiusonc.com - Gross Profitability|TuHURA Biosciences Inc. - Gross Margin|TARA - Gross Margin|FATE (Fate Therapeutics) - Return on Gross Profit|Return on Gross Profit Aadi Bioscience, Inc.|Return on Gross Profit TCRX|Gross Profitability CSBR|Gross Margin XBIT|Return on Sales by Gross Profit CEL-SCI Corp.|Gross Profitability ostherapies.com OSTX|RADX: Gross Return on Sales|ARTV: Return on Gross Profit|ANL (Adlai Nortye) - Gross Return on Sales|Veru (VERU) - Gross Profitability|Return on Gross Profit Tempest Therapeutics Inc|Gross Profitability Xilio Therapeutics|Gross Return on Sales RENB (Renovaro Inc.)|Gross Profitability Mural Oncology PLC (MURA)|Gross Margin Kairos Pharma (KAPA)|Gross Profitability onkuretherapeutics.com OKUR|GDTC: Gross Return on Sales|CRIS: Return on Gross Profit|apollomicsinc.com (APLM) - Return on Gross Profit|THAR: Gross Margin|Return on Gross Profit Advanced Biomed Inc.|Return on Gross Profit GNPX|Gross Return on Sales CLDI (Calidi Biotherapeutics)|Gross Margin SBFM|Gross Profitability SLRX (Salarius Pharma)|Kitov Pharma - Return on Gross Profit|American Oncology Network (AONC) - Gross Profit Margin|BeiGene - Gross Margin|Checkpoint Therapeutics, Inc. (CKPT) - Return on Gross Profit|ELEV (Elevation Oncology, Inc.) - Return on Gross Profit|iCAD Inc. - Gross Profit Rate|Return on Gross Profit IKNA|Gross Margin notablelabs.com|Return on Gross Profit VIRX (Viracta Therapeutics Inc.)|MOR - Gross Profit Margin|Gross Profitability NAYA Biosciences NAYA|AAPGV - Return on Gross Profit